CLYYF (Celyad Oncology) FCF Margin %: -53,075.00% (As of Dec. 2025)


CLYYF Celyad Oncology SA CLYYF
28 GF Score
Price $0.25
GF Value $0.15
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology FCF Margin %?

Celyad Oncology CLYYF 28 FCF Margin % is -53,075.00% as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Celyad Oncology ranks worse than 96.77% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Celyad Oncology's Free Cash Flow for the six months ended in Dec. 2025 was $-4.25 Mil. Celyad Oncology's Revenue for the six months ended in Dec. 2025 was $0.01 Mil. Therefore, Celyad Oncology's FCF Margin % for the quarter that ended in Dec. 2025 was -53,075.00%.

As of today, Celyad Oncology's current FCF Yield % is -59.29%.

The historical rank and industry rank for Celyad Oncology's FCF Margin % or its related term are showing as below:

CLYYF' s FCF Margin % Range Over the Past 10 Years
Min: -559680   Med: -9468.41   Max: -264.42
Current: -33425

During the past 13 years, the highest FCF Margin % of Celyad Oncology was -264.42%. The lowest was -559680.00%. And the median was -9468.41%.

CLYYF's FCF Margin % is ranked worse than
96.77% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs CLYYF: -33425.00

Celyad Oncology FCF Margin % Related Terms

Celyad Oncology FCF Margin % Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology FCF Margin % Chart

Celyad Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -15,853.15 -3,113.85 -32,320.00

Celyad Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12,904.76 -21,160.00 -1,657.22 -23,600.00 -53,075.00

CLYYF vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Celyad Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's FCF Margin % falls into.


CLYYF
28GF Score
Celyad Oncology SA CLYYF
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celyad Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Celyad Oncology's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-8.08/0.025
=-32,320.00 %

Celyad Oncology's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-4.246/0.008
=-53,075.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -53,075.00% mean?
Celyad Oncology (CLYYF) has a FCF Margin % of -53,075.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #928 out of 959 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Celyad Oncology's FCF Margin % too high?
Celyad Oncology's current FCF Margin % is -53,075.00%. Based on the distribution chart, Celyad Oncology ranks #928 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #928 out of 959 companies for FCF Margin %. This places Celyad Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current FCF Margin % is -53,075.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current FCF Margin % is -53,075.00%. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current FCF Margin % is -53,075.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued. The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15. GuruFocus considers Celyad Oncology to be Significantly Overvalued.

Key valuation signals for CLYYF:

  • FCF Margin %: -53,075.00%
  • GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score

Get the complete analysis for CLYYF

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.15
GF Value